drugset / Trial / NCT00604630

Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke

NCT00604630

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.

Timeline

Start
2003-01
Primary completion
2008-06
Completion
2008-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoetin alfa Protein / enzyme biologic 40000 iu Intravenous